Sai Parenterals Ltd
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
- Market Cap ₹ 2,189 Cr.
- Current Price ₹ 495
- High / Low ₹ 706 / 400
- Stock P/E 87.8
- Book Value ₹ 112
- Dividend Yield 0.00 %
- ROCE 5.28 %
- ROE 4.88 %
- Face Value ₹ 5.00
Pros
- Debtor days have improved from 253 to 173 days.
Cons
- Stock is trading at 4.41 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Tax rate seems low
- Company has a low return on equity of 8.64% over last 3 years.
- Company has high debtors of 173 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty IPO BSE Healthcare BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| 97 | 154 | 163 | 381 | 668 | |
| Sales growth | +59% | +6% | +134% | ||
| 78 | 122 | 124 | 342 | 581 | |
| Operating Profit | 19 | 32 | 39 | 39 | 86 |
| OPM % | 19% | 21% | 24% | 10% | 13% |
| 0 | 1 | 1 | 9 | 13 | |
| Interest | 6 | 11 | 12 | 19 | 32 |
| Depreciation | 6 | 9 | 8 | 17 | 47 |
| Profit before tax | 7 | 13 | 20 | 12 | 20 |
| Tax % | 40% | 33% | 28% | -20% | |
| 4 | 8 | 14 | 14 | 25 | |
| EPS in Rs | 1.19 | 2.28 | 3.92 | 3.23 | 5.35 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 58% |
| TTM: | 134% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 | 312 |
| Reserves | 24 | 61 | 80 | 469 | 184 |
| 69 | 119 | 94 | 469 | 374 | |
| 34 | 75 | 85 | 465 | 450 | |
| Total Liabilities | 134 | 268 | 272 | 1,424 | 1,320 |
| 44 | 70 | 53 | 364 | 377 | |
| CWIP | 2 | 0 | 0 | 212 | 269 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 88 | 198 | 219 | 848 | 674 | |
| Total Assets | 134 | 268 | 272 | 1,424 | 1,320 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -13 | -30 | 33 | 93 | |
| -19 | -46 | 0 | -274 | |
| 24 | 79 | -36 | 596 | |
| Net Cash Flow | -8 | 2 | -2 | 415 |
| Free Cash Flow | -30 | -72 | 41 | -184 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -54% | -94% | 86% | 253% |
Ratios
Consolidated / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 231 | 302 | 283 | 173 |
| Inventory Days | 83 | 143 | 199 | 259 |
| Days Payable | 140 | 203 | 225 | 224 |
| Cash Conversion Cycle | 174 | 242 | 256 | 208 |
| Working Capital Days | 19 | 72 | 79 | -161 |
| ROCE % | 16% | 17% | 5% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Group-wide capacity utilisation % |
|
|||
| Cumulative product registrations in regulated markets count |
||||
| Dossiers approved/filed in the year count |
||||
| Dossiers developed in-house by R&D subsidiary (cumulative) count |
||||
| Dossiers under development (pipeline) count |
||||
| Group installed manufacturing capacity million units |
||||
| Number of complex products in portfolio count |
||||
| Pharmacy reach in Australia via long-term supply networks count |
||||
| Share of consolidated revenue from long-term supply contracts in regulated markets % |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Subsidiary SP Analytics to acquire majority stake in Bion Therapeutics’ prescription business by month-end.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday, 16Th November, 2026
- Sai Parenterals to acquire majority stake in Bion Therapeutics via SP Analytics by 30 Nov 2026.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Call conducted on Monday the 2nd day of November, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Un-audited financial results for the quarter and half-year ended 30th September, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q2 FY2027 earnings call held on 2 November 2026 is now available.
Concalls
-
Nov 2026Transcript PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT
Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.